Depression & Anxiety in Adolescents

Similar documents
Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Children s Hospital Of Wisconsin

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Quick Guide to Common Antidepressants-Adults

Child & Adolescent Psychiatry (a brief overview)

Adult Depression - Clinical Practice Guideline

Average dose zoloft for ocd and anxiety

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Management Of Depression And Anxiety

Depression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms

Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School

Psychiatry in Primary Care: What is the Role of Pharmacist?

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

5 COMMON QUESTIONS WHEN TREATING DEPRESSION

Antidepressant Selection in Primary Care

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Joel V. Oberstar, M.D. 1

Illuminating the Black Box: Antidepressants, Youth and Suicide

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

Zoloft (sertraline) FDA ALERT [05/2007] Suicidal Thoughts or Actions in Children and Adults

Short Clinical Guidelines: General Anxiety Disorder (GAD)

Depression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:

Depression. University of Illinois at Chicago College of Nursing

Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6

Disclosures. Questions. A Developmental Approach. Goals and objectives 4/3/2018 FEARS AND TEARS: TREATING ANXIETY AND DEPRESSION IN PRIMARY CARE

Depression: Identification, Evaluation and Management in Primary Care

Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University

Realities of Depression in Primary Care Setting

Disclosure Information

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

Clinical Update on Management of Depression and Anxiety in the Primary Care Setting. Objectives: Why Is This Important?

Treatment of Anxiety (without benzos)

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

Reviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options

Psychiatric Medication Guide

Treatment of Major Depressive Disorder

Pediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1

Treating Childhood Depression in Pediatrics. Martha U. Barnard, Ph.D. University of Kansas Medical Center Pediatrics/Behavioral Sciences

Depression: Identification, Evaluation and Management in Primary Care

ANTI-DEPRESSANT MEDICATIONS

2/23/18. Age of Anxiety: Transforming Qualms into Calm. Disclosures. Objectives. I have nothing to disclose

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

Depression and Anxiety in

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Depression: Identification, Evaluation and Management in Primary Care

8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation

Schedule FDA & literature based indications

Anxiety and Depression Management for General Providers

An Overview of Anxiety and Mood Disorders in Youth

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

Treatment of Depression in the Primary Care Office

Treating Chronic Illness in the PCMH Handout - Depression. A. Guidelines. 1. Control of Symptoms:

Recognizing Depression and Restoring Mood and Well- Being in the Older Patient

WILL LEXAPRO HELP DEPRESSION

Overview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

Consultant Pharmacist Approach to Major Depressive Disorder

Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO

Antidepressant Selection in Primary Care

Depression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.

Assessing and Treating Depression and Anxiety in Children with Cancer Anna (Nina) Muriel, MD, MPH

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

CITIZENS PETITION TO FOOD AND DRUG ADMINISTRATION. Division of Dockets Management Food and Drug Administration Room Fishers Lane

MOOD (AFFECTIVE) DISORDERS and ANXIETY DISORDERS

Recognizing and Managing Depression in Primary Care

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Antidepressant Medication Therapy in Primary Care July 25, 2013

%, # Southern Medical Association July / 01/ /7 23 #, 2 3

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

Depression & Suicide 7/11/2017 DISCLOSURES. DSM 5 Depressive Disorders. Objectives

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

Diabetes and Depression. Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C

Does cymbalta cause weight gain

Moderate depression, low/moderate safety risk, age < 12

Assessment & Management of Depression in Palliative Care

Optimistic News and Practical Tools. The Role of Primary Care in Screening and Managing Teen Depression

Chronic Pain Care Management in Primary Care 12/16/2010. Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences

Major Depressive Disorder

Your journal: how can it help you?

Kessler 1994; Kessler 1995; DSM-IV-TR 2000.

The Pharmacist's Role in Major Depressive Disorder: Optimizing Care. Welcome We will begin shortly.

Disclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*

Clinical Policy: Vilazodone (Viibryd) Reference Number: CP.PMN.145 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Treating Depression in Adults

Some newer, investigational approaches to treating refractory major depression are being used.

ERIC J. NESTLER, MD, PhD

ADHD and. Shaw Wendi Fortuchang, M.D. Board certified in Child & Adolescent, Adult, and Forensic Psychiatry

5/12/11. Educational Objectives. Goals

Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests

How to Manage Anxiety

Depression. By Uju Chukwuka, BSN, RN.

Major Depression and Anxiety in Adolescents and Adults

Focusing on Depression in the Community. Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy

Transcription:

Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with medication management»kristin M. Rager, MD, MPH, FAAP, FSAHM What is normal? Normal does not mean always happy, always easy Teens have a lot going on, physical, social, and cognitive changes, which can make their behaviors seem abnormal to adults at times Normal does not mean significantly impaired function this is out of the realm Depression Diagnosis 5 of the following during same 2 week period and a significant change from baseline 1. Depressed or irritable mood 2. Decreased interest or lack of enjoyment 3. Decreased concentration or indecision 4. Insomnia or hypersomnia Depression Diagnosis SIGECAPS or DIGSPACES 5. Change of appetite or change of weight 6. Excessive fatigue 7. Feelings of worthlessness or excessive guilt 8. Recurrent thoughts of death or suicidal ideation 9. Psychomotor agitation or retardation Sleep Interest Guilt Energy Concentration Appetite Psychomotor Suicidality Depressed mood Interest Guilt Sleep Psychomotor Appetite Concentration Energy Suicidality 1

Anxiety Diagnosis Excessive worry more days than not for at least 6 months about a number of events and they find it difficult to control the worry 3 or more of the following symptoms: Restlessness or feeling keyed up or on edge easily fatigued difficulty concentrating, irritability muscle tension sleep disturbance Causes significant distress or impairment PHQ Scoring GAD 7 Total Score Depression Severity 1-4 Minimal depression 5-9 Mild depression 10-14 Moderate depression 15-19 Moderately severe depression 20-27 Severe depression GAD 7 Scoring» 5-9 mild anxiety» 10-14 moderate anxiety» 15 and up severe anxiety First and most important step. Identifying those teens who need help 2

Treatment OPTIONS Psychotherapy Should be recommended to ALL patients with depression or anxiety May be through multiple different venues! Medication Psychotherapy PLUS Medication Selective serotonin reuptake inhibitors (SSRI s) Medication should be recommended to all patients with moderate to severe depression May consider therapy alone first in mildly affected Child and Adolescent Anxiety Multimodal Study (CAMS) SSRI and CBT led to signif clinical improvement in 80% Treatment for Adolescents with Depression (TADS) study SSRI and CBT led to significant clinical improvement in 71% Psychotherapy Medications Cognitive behavioral therapy (CBT) - helps patient recognize and change negative patterns of thinking that may contribute to depression Significant evidence for its efficacy SSRI s Fluoxetine (Prozac) Paroxetine (Paxil) Sertraline (Zoloft) Citalopram (Celexa) Escitalopram (Lexapro) Viibryd (Vilazodone) 3

Fluoxetine (Prozac) Fluoxetine Dosing FDA Indications- MDD 8 yo and above and OCD 7 yo and above, BN and PD 18 and above Longest ½ life (1-3 days after a single dose) May help prevent relapse as well (40% at 2 years without treatment) Starting dose 10 mg daily Target dose 20 mg daily Maximum dose 60 mg daily Sertraline (Zoloft) Paroxetine (Paxil) FDA Indications -MDD, PD, PTSD, SAD, PMDD 18 and over, OCD 6 yo and above Dosing Starting dose 25 mg daily Target dose 50 mg daily Maximum dose 200 mg daily Several studies have found no indication of efficacy against depression in adolescents FDA 2003 strongly advises against its use in patients under 18 years old There is currently no evidence that Paxil is effective in children or adolescents with MDD Citalopram (Celexa) Escitalopram (Lexapro) FDA Indication - MDD 18 and over Adult Starting dose 20 mg daily Target dose 40 mg daily Maximum dose 40 mg daily FDA Indication - MDD 12 yo and above and GAD 18 and above Starting dose 10 mg daily Target dose 10 mg daily Maximum dose 20 mg daily 4

Vilazodone (Viibryd) Liquid Formulations No FDA Pediatric Indication - MDD 18 and above Starting dose 10 mg daily Target dose 20 mg daily Maximum dose 40 mg daily» Fluoxetine 20mg/5 ml» Sertraline 20mg/1 ml» Escitalopram 5mg/5ml» Citalopram 10/5ml SSRI tidbits Side effects of SSRI s Start low, go slow (increase from starting dose to target dose after 1-2 weeks) Improvement is not instantaneous Symptoms begin to improve 2-4 weeks after target dose is reached 30 40% of teens do not respond to the initial treatment at all Generally well tolerated with minimal or no side effects Generally increase with increase in dose Usually subside in 1-2 weeks Most commonly headache, abdominal pain, nausea, diarrhea, sleep changes, jitteriness Side effects of SSRI s Why the black box? Changes in sexual functioning (decreased libido, delayed ejaculation, anorgasmia) Can induce mania or hypomania in those with bipolar disorder Suicidality??? 23 trials involving more than 4300 children and adolescents NO suicides in any of these studies Information was looked at 2 ways 5

Black Box Warning Suicidality and the Black Box Warnings Did not prohibit use of the medications in youth, but called on physicians and parents to closely monitor children and adolescents who are taking antidepressants for a worsening in symptoms of depression or unusual changes in behavior. As of May 2007 includes young adults 18-24 years October 15, 2004 FDA directed pharmaceutical companies to label all antidepressants with the warning that they "..increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents with major depressive disorder (MDD) or other psychiatric disorders Black Box Warning Adverse Event Reports States that the increased risk of suicidal thinking and/or behavior in a small proportion of children and adolescents is most likely to occur during the early phases of treatment Reports made by the investigator if the patient spontaneously reports a side effect (suicidal thoughts) 4% in patients on meds 2% in those on placebo When patients were asked about suicidal thoughts and behaviors at each visit Existing suicidality was not increased nor was new suicidality produced by meds Suicidal thoughts were decreased SO what happened in response In the year following the Black Box, in those less than 17 years old Overall prescribing of antidepressants decreased by 10% New prescriptions decreased by 20% 6

In addition What to do instead of not prescribing - Close Monitoring The overall rate of suicide in the 10-19 year age range has declined by 25% over the past decade This decade has been associated with a dramatic increase in the prescription rates of SSRI s If meds increased suicidal behaviors, you would expect an increase in the suicide rate as prescriptions went up Weekly for the first 4 weeks Every other week for the next 4 weeks After 12 weeks Then as clinically indicated SSS symptoms, sides, suicidality How long to stay on meds? What if first med doesn t work? I feel better now, so I stopped my Prozac Should continue for 9-12 months after the patient is back to normal Relapse is significantly higher if meds are stopped sooner Should taper dose down to prevent discontinuation syndrome decrease the dose by 25 to 50% weekly» 6-12 weeks at therapeutic dose» try 2nd ssri and/or ADD THERAPY» after 6-12 weeks at therapeutic dose» try other med and/or ADD THERAPY Other Meds» Bupropion (Welbutrin)» aminoketone for MDD, SAD 18 and over» Venlafaxine (Effexor)» SNRI for MDD, GAD, SAD, PD 18 and over» Desvenlafaxine (Pristiq)» SNRI for MDD 18 and over» Duloxetine (Cymbalta)» SNRI for MDD, GAD, Pain, FM 18 and over Other other meds» Buspirone (Buspar)» Non benzo anxiolytic» Hydroxyzine» Antihistamine» Benzos» in general, just no 7

Conclusions Conclusions Depression and anxiety are national public health problems for children and adolescents Both are serious medical illness and may be potentially lethal because of the risk of suicide. When recognized and correctly diagnosed, depression and anxiety can be treated successfully A combination of therapeutic approaches should be utilized, preferably medication AND psychotherapy individualized to the needs of a teen and his or her family Thanks! Questions» rager@ragermd.com 8